SMS Pharmaceuticals Complete Financial Statements
In FY2026, SMS Pharmaceuticals (SMSPHARMA) reported revenue ₹241 Cr, net profit ₹33 Cr and EPS ₹3.58, with a net profit margin of 13.7% and ROE of 4.2%. Full financial statements from FY2016 to FY2026 (11 years) — income statement, balance sheet and cash flow in ₹ Crores. Download as Excel or CSV. Review SMSPHARMA earnings valuation to evaluate earnings-based valuation against sector peers.
Complete Financial Data Export
Profitability Ratios
Balance Sheet Ratios
SMSPHARMA Revenue, Net Profit & EBITDA — Year-on-Year Growth
SMSPHARMA YoY (Mar 2025 vs Mar 2026) — revenue -3.6%, net profit +65.0%, EBITDA +2.4%, expenses -4.3%. Explore SMS Pharmaceuticals intrinsic price to estimate fundamental worth using multiple valuation models.
SMSPHARMA Income Statement — Revenue, EBITDA & Net Profit
SMS Pharmaceuticals revenue ₹241 Cr, EBITDA ₹43 Cr, net profit ₹33 Cr, EPS ₹3.58 (2026) — net profit margin 13.7%. For live price, earnings ratios and company overview, see SMSPHARMA share price screener.
| Particulars | Mar 2026 | Sept 2025 | Mar 2025 | Jun 2025 | Dec 2025 | Sept 2024 | Mar 2024 | Jun 2024 | Dec 2024 | Sept 2023 | Mar 2023 | Jun 2023 | Dec 2023 | Sept 2022 | Mar 2022 | Jun 2022 | Dec 2022 | Sept 2021 | Mar 2021 | Jun 2021 | Dec 2021 | Sept 2020 | Mar 2020 | Jun 2020 | Dec 2020 | Sept 2019 | Mar 2019 | Jun 2019 | Dec 2019 | Sept 2018 | Jun 2018 | Dec 2018 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 241 | 244 | 250 | 197 | 214 | 198 | 248 | 166 | 176 | 167 | 151 | 136 | 163 | 160 | 61 | 65 | 151 | 176 | 173 | 164 | 123 | 131 | 100 | 114 | 150 | 119 | 105 | 118 | 81 | 136 | 126 | 102 |
| Expenses | 198 | 194 | 207 | 157 | 167 | 165 | 212 | 131 | 140 | 139 | 126 | 109 | 133 | 146 | 65 | 65 | 130 | 128 | 130 | 119 | 94 | 107 | 82 | 91 | 114 | 96 | 88 | 94 | 60 | 110 | 101 | 76 |
| EBITDA | 43 | 50 | 42 | 40 | 47 | 33 | 35 | 35 | 35 | 29 | 25 | 27 | 31 | 14 | -4 | 0 | 21 | 48 | 42 | 46 | 29 | 25 | 18 | 22 | 35 | 23 | 16 | 24 | 21 | 27 | 24 | 26 |
| Operating Profit Margin % | 17.00% | 20.00% | 16.00% | 20.00% | 21.00% | 16.00% | 14.00% | 20.00% | 19.00% | 17.00% | 16.00% | 19.00% | 18.00% | 9.00% | -7.00% | -1.00% | 12.00% | 27.00% | 24.00% | 27.00% | 22.00% | 18.00% | 15.00% | 19.00% | 23.00% | 19.00% | 15.00% | 20.00% | 25.00% | 19.00% | 19.00% | 25.00% |
| Depreciation | 10 | 10 | 9 | 10 | 10 | 9 | 8 | 8 | 9 | 8 | 8 | 8 | 8 | 8 | 8 | 8 | 8 | 8 | 6 | 8 | 8 | 6 | 6 | 6 | 6 | 5 | 5 | 5 | 5 | 5 | 5 | 5 |
| Interest | 5 | 6 | 5 | 6 | 6 | 5 | 6 | 5 | 4 | 6 | 6 | 6 | 6 | 5 | 4 | 5 | 6 | 5 | 3 | 5 | 5 | 3 | 3 | 3 | 3 | 3 | 3 | 3 | 3 | 3 | 3 | 3 |
| Profit Before Tax | 27 | 34 | 29 | 24 | 31 | 20 | 22 | 22 | 22 | 15 | 11 | 13 | 17 | 1 | -16 | -13 | 7 | 35 | 34 | 33 | 16 | 16 | 9 | 14 | 27 | 14 | 8 | 15 | 13 | 19 | 16 | 19 |
| Tax | -6 | 9 | 8 | 4 | 8 | 5 | 5 | 5 | 4 | 3 | 4 | 3 | 5 | 3 | -23 | 0 | 3 | 12 | 11 | 9 | 7 | 5 | 2 | 7 | 5 | 5 | -5 | 8 | 5 | 9 | 9 | 9 |
| Net Profit | 33 | 25 | 20 | 21 | 24 | 14 | 17 | 17 | 18 | 12 | 6 | 9 | 12 | -2 | 6 | -13 | 4 | 23 | 23 | 24 | 9 | 11 | 6 | 7 | 21 | 10 | 13 | 8 | 8 | 10 | 7 | 9 |
| Earnings Per Share (₹) | 3.58 | 2.84 | 2.40 | 2.31 | 2.59 | 1.67 | 2.04 | 1.95 | 2.15 | 1.39 | 0.73 | 1.10 | 1.36 | -0.24 | 0.73 | -1.51 | 0.44 | 2.72 | 2.73 | 2.78 | 1.07 | 1.30 | 0.76 | 0.83 | 2.53 | 1.17 | 1.57 | 0.92 | 0.90 | 1.19 | 0.85 | 1.11 |
SMSPHARMA Balance Sheet — Assets, Liabilities & Shareholders' Equity
SMSPHARMA total assets ₹1,362 Cr, total equity ₹786 Cr, total liabilities ₹ Cr (2026) — ROE 4.2%.
| Particulars | 2026 | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| ASSETS | |||||||||||
| Total Assets | 1,362 | 1,153 | 1,034 | 880 | 860 | 812 | 608 | 559 | 503 | 493 | 656 |
| Current Assets | 638 | 555 | 534 | 411 | 377 | 309 | 219 | 208 | 169 | 157 | 248 |
| Fixed Assets | 656 | 533 | 437 | 412 | 438 | 457 | 281 | 281 | 279 | 291 | 370 |
| Capital Work in Progress | 122 | 35 | 30 | 33 | 11 | 7 | 42 | 18 | 8 | 8 | 13 |
| Investments | 351 | 12 | 11 | 11 | 22 | 27 | 26 | 27 | 28 | 29 | 0 |
| Other Assets | 0 | 573 | 556 | 424 | 389 | 321 | 260 | 232 | 187 | 166 | 272 |
| LIABILITIES | |||||||||||
| Total Liabilities | |||||||||||
| Current Liabilities | 224 | 189 | 166 | 164 | 193 | 206 | 115 | 94 | 97 | 91 | 162 |
| Non-Current Liabilities | |||||||||||
| SHAREHOLDERS' EQUITY | |||||||||||
| Total Equity | 786 | 640 | 536 | 461 | 470 | 411 | 348 | 322 | 285 | 255 | 294 |
| Share Capital | 9 | 9 | 9 | 9 | 9 | 9 | 9 | 9 | 9 | 9 | 9 |
| Reserves & Surplus | 776 | 615 | 499 | 452 | 462 | 402 | 340 | 314 | 276 | 246 | 285 |
SMSPHARMA Cash Flow Statement — Operating, Investing & Financing
SMS Pharmaceuticals operating cash flow ₹82 Cr, investing ₹-123 Cr, financing ₹47 Cr, net cash flow ₹5 Cr (2025).
| Particulars | March 2025 | March 2024 | March 2023 | March 2022 | March 2021 | March 2020 | March 2019 | March 2018 | March 2017 | March 2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating Activities | 82 | 50 | 23 | 45 | 90 | 40 | 50 | 32 | 74 | 61 |
| Investing Activities | -123 | -52 | -30 | -27 | -152 | -43 | -35 | -17 | -39 | -97 |
| Financing Activities | 47 | 31 | -32 | -12 | 92 | -2 | -13 | -15 | -33 | 27 |
| Net Cash Flow | 5 | 29 | -39 | 6 | 31 | -5 | 2 | 0 | 1 | -9 |